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Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by a systemic dysfunction of T-cells. In this study
we tested the impact of DMARD and anti-TNF agents on short-term activation characteristics of T-cells. We enrolled 12
patients with newly diagnosed RA (naı¨ve RA) who were treated with methothrexate (MTX) and glucocorticsteroid (GCS) and
22 patients with established RA non responding to conventional DMARD therapy who were treated with different anti-TNF
agents. Nine healthy volunteers served as controls. Blood samples were taken at baseline, then at 4th and 8th week of
therapy. The characteristics of several intracellular activation processes during short-term activation of T-cells including
cytoplasmic Ca2+ level, mitochondrial Ca2+ level, reactive oxygen species (ROS) and nitric oxide (NO) generation were
determined by a novel flow-cytometry technique. At baseline, the tested processes were comparable to controls in naı¨ve
RA. During GCS therapy, cytoplasmic Ca2+ level and ROS generation decreased. After the addition of MTX to GCS
cytoplasmic Ca2+ level became comparable to controls, while ROS generation decreased further. In DMARD non responders,
cytoplasmic Ca2+ level was higher than controls at baseline. The cytoplasmic Ca2+ level became comparable to controls and
ROS generation decreased during each of the three anti-TNF-a agent therapies. Mitochondrial Ca2+ level and NO generation
were unaltered in all of the patient groups. These results indicate that intracellular machinery is affected in T-cells of RA
patients. This may alter the behavior of T-cells during activation. Different therapeutic approaches may modulate the
abnormal T-cell functions.
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Introduction
Rheumatoid arthritis (RA) is the most common chronic
autoimmune joint disease [1]. It has long been recognized that
the immune phenotype (i.e. the prevalences of T-cell subsets) in
RA is altered both in the synovium and in the peripheral blood
[2,3]. Besides the alterations observed in the immune phenotype,
there is increasing evidence in support of the notion that abnormal
lymphocyte functions also contribute to the pathogenesis of RA.
Specifically, an increased level of nitric oxide (NO) production [4],
altered Ca2+ signaling [5] and the enhanced production of reactive
oxygen species (ROS) [6] during activation are hallmarks of a T
lymphocyte dysfunction in RA.
Several types of traditional disease-modifying anti-rheumatic
drugs (DMARDs) and immunesuppressive agents have been
demonstrated to influence the T-cell subset distribution and
function, and it is increasingly acknowledged that this action may
contribute to the therapeutic effects of such drugs [7]. Recently,
we investigated in a follow-up study the changes in T-cell subsets
in RA patients in response to conventional DMARD and
biological therapies [8], but intracellular activation characteristics
in response to these therapies are lacking at present. Moreover, no
data are available as to whether the effects on T-cell function differ
between individual types of anti-TNF-a agents. We have,
therefore, performed a comprehensive follow-up investigation of
a variety of T-cell functional parameters including cytoplasmic
Ca2+ level, ROS generation, NO production and mitochondrial
Ca2+ level in activated T-cells before and during the administra-
tion of synthetic DMARDs or three different anti-TNF-a agents
[adalimumab (ADA), etanercept (ETA) and infliximab (IFX)].
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Materials and Methods
Patients
Twelve patients with naiv RA and twenty two patients with
established RA were enrolled in the study. The detailed clinical
data and patient characteristics are presented in Table 1.
The naı¨ve RA group (n = 12) had not received any treatment
prior to our study. After the established RA diagnosis, DMARD
therapy was initiated according to a fixed protocol, which was in
agreement with current EULAR and Hungarian National
treatment guidelines [9]. This included the administration of
medium-dose oral glucocorticosteroid (GCS, methylprednisolone,
16 mg/day) alone for 4 weeks; then GCS was tapered to 8 mg/
day and methotrexate (MTX) was started with a dose of 10 mg/
week. Blood samples were taken before the initiation of DMARD
therapy (baseline), then after 4 and 8 weeks of treatment (i.e. after
4 weeks on medium-dose GCS and after a further 4 weeks of
combination therapy with tapered-dose GCS+MTX).
In the DMARD nonresponding group with established RA
(n= 22) unresponding to standard DMARD combination therapy
[i.e. MTX at 15 mg/week and leflunomide (LF) at 20 mg/day],
anti-TNF-a therapy was initiated following the standard-of-care
decision of the treating physician: ADA at 40 mg/2 weeks sc
(n = 8); ETA at 50 mg/week sc (n = 7); or IFX on week 0, 2 and 6
at 3 mg/kg iv (n = 7). At this time, LF was discontinued, while
MTX was given simultaneously. Blood samples were taken before
the initiation of each anti-TNF-a agent (baseline), and then on
Week 4 and 8 of therapy just before the administration of the
actual dose of the drug. There were no differences in the baseline
characteristics (age, disease duration, disease activity, rheumatoid
factor etc.) of the patients in the different anti-TNF-a groups.
The nine age- and gender-matched healthy volunteers who
served as controls had a negative history of rheumatic symptoms
and a negative status upon detailed physical and laboratory
examination. Written informed consent was obtained in advance
from all participants. The project was approved by the Ethical
Committee of the University of Szeged (ETT-TUKEB 905/PI/
09). This study was conducted in full accordance with the
Declaration of Helsinki (1964).
Cell preparation
Similarly to our previous study [10], 18 ml of lithium-heparin-
anticoagulated blood was taken from all participants for the
investigation of T-cells. Peripheral blood mononuclear cells
(PBMCs) were separated by gradient centrifugation with Ficoll-
Paque (GE Healthcare Life Sciences, Pittsburgh, PA, USA),
washed twice with phosphate-buffered saline pH 7.4 (PBS; Central
Pharmacy of Semmelweis University, Budapest, Hungary). The
PBMCs were resuspended in modified RPMI medium (Sigma–
Aldrich, St. Louis, MO, USA), the Ca2+ concentration of which
was set to 2 mM. Samples were incubated with Fluo 3 AM, Rhod2
AM, dihydroethidium and DAF-FM diacetate (Molecular Probes,
Carlsbad, CA, USA), which are sensitive to the cytoplasmic Ca2+
level, the mitochondrial Ca2+ level, the concentration of ROS and
the level of nitric oxide, respectively. The staining conditions were
identical to those reported previously [11]. Fluorescence signals
were monitored for up to 10 min after the addition of
phytohaemagglutinin (PHA) (Sigma–Aldrich, St. Louis, MO,
USA), a non-specific activator of T-cells, in a final concentration
of 20 mg/ml.
Cells were also stained with dyed antibodies against CD4
markers (Becton Dickinson, San Diego, CA, USA) allowing us to
gate the cell populations to be monitored during activation.
Equipment and statistical analysis
All measurements were performed on a BD FACSAria flow
cytometer (Becton Dickinson, San Jose, CA, USA). The kinetic
parameters of intracellular processes were determined by using R
(R Foundation for Statistical Computing, Vienna, Austria) as
follows. The measurement time-frame was divided into 100 time
intervals of equal length and the median values were calculated in
each interval. The smoothing method of Lowess was applied to the
median values and each value was referred to that measured at the
beginning of the experiment, furnishing the relative parameter
value, rpv. The following parameters were calculated from the rpv
data: area under the curve (AUC), the maximum value (Max) and
the time required to reach Max (tmax) (Figure 1). One unit (U) of
the AUC is defined as a rpv of 1 in 1second. Detailed explanation
of these parameters is published in a previous study [12].
Further statistical analysis based on the values of these
parameters was performed with R and the Statistica 7 software
package (Statsoft, Tulsa, OK, USA). The Mann-Whitney test was
applied for the comparison of the data on the controls and the
patients, while the paired data in each related patient group were
compared by the Friedman test. When the Friedman test
demonstrated significant differences, the post hoc Dunn test was
used to identify which pairs were significantly different. Levels of
p,0.05 were taken as statistically significant. The clinical data in
Table 1 and the results in Table 2 are given as median
[interquartile range].
Results
Naı¨ve RA patients subjected to DMARD therapy
At baseline, the investigated intracellular parameters of the T-
cells during short-term activation were similar to those of the
controls (Table 2, Figure 2). At Week 4 of GCS therapy, the
cytoplasmic Ca2+ response and the level of ROS production
during T-cell activation had decreased significantly and become
lower compared to the controls and the baseline values. At Week
8, cytoplasmic Ca2+ response had become comparable to the
baseline and control levels, while the ROS production was further
impaired.
DMARD nonresponder patients subjected to anti-TNF-a
agents
At baseline, the cytoplasmic Ca2+ level was higher in this patient
group than in the controls (Table 2, Figure 2). The other
parameters investigated, including the mitochondrial Ca2+ levels,
ROS and NO production were comparable to those observed in
the controls with the exception of the subgroup treated later with
ETA. (These patients exhibited an increased ROS generation
capacity at baseline).
On Week 4 of anti-TNF-a therapy, the cytoplasmic Ca2+ level
became comparable to controls, while ROS generation was
decreased significantly to below the baseline, irrespective of the
nature of the anti-TNF-a agent administered (including ETA). At
this time point, the other parameters investigated were still
comparable to those at the baseline in each patient group.
At Week 8, no significant alterations were detected relative to
Week 4 in any of the parameters tested.
Discussion
This is the first study that provides a follow-up of T-cell
activation characteristics in RA patients subjected to different
therapeutic regimes. Our study involved two different RA groups:
naı¨ve RA and DMARD-non responding patients.
T-Cell Activation in Patients with Rheumatoid Arthritis
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Naı¨ve patients
There is a paucity of studies investigating T-cell activation
characteristics in RA. The few data available suggest that
increased levels of nitric oxide [13], intracellular Ca2+ [4] and
ROS [6] are present in the T-cells of active RA patients and these
abnormalities may contribute to the cellular dysfunction. Howev-
er, in naı¨ve RA patients we found that these parameters were
comparable to those in the controls. The discrepancy between our
results and previous studies could be due to the different
populations tested as we enrolled newly diagnosed naı¨ve RA
subjects, while the published data involved a less specific RA
population. Indeed, as we discovered in the case of patients who
had suffered from RA for several years, these intracellular
mechanisms may be affected in the later stage of the disease that
does not respond to DMARD therapy.
The cytoplasmic Ca2+ response and ROS production during the
short-term activation of T lymphocytes were suppressed relative to
the baseline after 4 weeks of GCS therapy. In in vitro and in vivo
animal studies GCS inhibited activated T-cell functions at several
points of the intracellular signaling cascade [14]. GCS treatment
limits PIP2 hydrolysis and IP3 production [15], down-regulates
IP3 receptors [16] and also depletes internal Ca2+ stores [17].
Irrespective of the mechanism, the result at a cellular level is the
reduction of the Ca2+ responses during short-term T-cell
activation. GCS therapy also decreased intracellular ROS levels
in human aortic smooth muscle cells [18]. These reported data are
in accordance with our results indicating that GCS therapy has a
major impact on the T-cell functionality in early RA.
After 1 month of MTX treatment, the cytoplasmic Ca2+
response during T-cell activation became comparable to controls.
An in vitro animal study revealed evidence that MTX has IP3-like
properties and mobilizes Ca2+ from the endoplasmic reticulum in
a direct way without receptor activation [19]. The increase in the
cytoplasmic Ca2+ level may reflect this effect (while it is still
uncertain whether the normal appearance of the cytoplasmic Ca2+
level does indicate normal Ca2+ signaling in this situation).
In MTX-treated subjects, ROS generation was suppressed
further. This phenomenon confirms previous results observed on
RA synoviocytes, where MTX inhibited the production of ROS
[20]. This finding may be of major clinical relevance, as excessive
ROS production plays a critical role in the pathogenesis of RA
[21]. Besides the role of extracellular ROS generation, it has also
been demonstrated that increased intracellular ROS production
amplifies the synovial inflammatory–proliferative response [22]
and is characteristic of and augments the T-cell dysfunction in RA
[23].
RA patients unresponding to DMARD therapy
In the second part of our study, we monitored T-cell
functionality of RA patients on anti-TNF-a therapy. We also
investigated whether different agents procure different effects on
these parameters.
At baseline, (i.e. just before anti-TNF-a therapy) we found a
higher cytoplasmic Ca2+ response to stimulation than in the
controls. It was noteworthy that the increased Ca2+ signal became
comparable to controls by Week 4 and remained unaltered at
Week 8, irrespectively of the anti-TNF-a agent used. Although this
occurred in almost all the patients, it is in contradiction with most
of the published data that suggest hyporesponsiveness of the T-
lymphocytes in RA [24,25].
The explanation of the discrepancy between the published and
our own data is probably the different characteristics of the RA
patients enrolled. The enrolled patients in the published studies
were predominantly treated with NSAIDs (with no reported effect
on the calcium metabolism in the T-cells). In contrast, we collected
samples from patients who did not respond to DMARD therapy
(that included MTX and LF). No effect of LF on T-cell Ca2+
signaling is known, while MTX has been documented to increase
Ca2+ response. When LF was replaced by any of the anti-TNF-a
agents, the cytoplasmic Ca2+ signal became comparable to
controls. It is unclear whether this is due to the introduction of
the anti-TNF-a agent and/or to the cessation of LF. Irrespective of
the mechanism, our results should be regarded as characteristic of
this specific RA subgroup. It is tempting to postulate that an
increased cytoplasmic Ca2+ signal might possibly be used as a
surrogate marker for the identification of RA patients in whom
combination of MTX with leflunomide will not be sufficient and
leflunomide is recommended to be replaced by an anti-TNF agent.
This hypothesis should be evaluated further.
Figure 1. Schematic demonstration of kinetic parameters of the investigated intracellular processes during the activation of T-
lymphocytes. Max = Maximum value, tmax = Time to reach maximum.
doi:10.1371/journal.pone.0104298.g001
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While our results also indicate that NO production and
mitochondrial Ca2+ handling are not affected during short-term
T-cell stimulation by anti-TNF agents in RA, we observed changes
in intracellular ROS production during anti-TNF therapy. As
discussed above, an increased intracellular ROS production may
contribute to the prolonged inflammation observed in RA, and a
reduction of ROS may therefore be a beneficial effect. We also
found that the baseline ROS production was higher in the ETA-
treated group and tended to be higher in the ADA group than in
the controls. Although the overproduction of TNF-a is thought to
be the main contributor to the increased ROS generation in RA,
the effects of anti-TNF-a treatment have not been extensively
studied in this RA patient subgroup.
The effect of anti-TNF agents on T-lymphocyte ROS
production is not fully elucidated. Data are limited to neutrophils.
Pay et al reported that IFX inhibited the production of ROS in
neutrophils in vitro [26], while anti-TNF-a treatment has been
stated to be ineffective on ROS production of the neutrophils in
RA patients [27,28]. For T-lymphocytes, we demonstrated a
significant decrease in all groups at Week 4 of anti-TNF-a therapy,
irrespective of whether the baseline ROS production was higher
than or comparable to the controls. This effect was most
pronounced in the IFX-treated group and proved to be associated
with significantly decreased ROS production. At Week 8, we
found no changes in the production of ROS relative to that at
Week 4; again, this type of anti-TNF action was comparable in the
various treatment groups.
The limitations of our work
Evaluating these results one should note that because of the low
number of patients enrolled, these observations are suitable for just
hypothesis generation and the data can not be extrapolated to
large patient cohorts.
In the DMARD nonresponding patients at initiation of anti-
TNF-a therapy leflunomide was discontinued, but we could not
investigate whether this effects the intracellular processes in any
way.
Conclusions
This study on peripheral blood samples has provided compre-
hensive information regarding the functionality of T-cells in RA.
The intracellular T-cell activation processes (including cytoplas-
mic Ca2+, ROS, NO generation and mitochondrial Ca2+) during
short-term T-cell activation were not altered in early RA. The
therapeutic interventions exerted specific effects on the different
parameters. GCS decreased cytoplasmic Ca2+ signal and the levels
of ROS. Tapering the GCS dose and the introduction of MTX
increased the cytoplasmic Ca2+ signal, but further decreased the
levels of ROS. In DMARD non responding patients, the
cytoplasmic Ca2+ level was higher than in the controls (possibly
due to the treatment with MTX). After the introduction of TNF a
inhibitors, the cytoplasmic Ca2+ signal became comparable to
controls and the levels of ROS decreased. The extent of NO
generation and the level of mitochondrial Ca2+ were not altered at
any time during our study.
These results indicate that intracellular machinery is affected in
T-cells of RA patients. This may alter the behavior of T-cells
during activation. Different therapeutic approaches may modulate
the abnormal T-cell functions.
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